R.-P. Perng - Concepedia

Author

R.-P. Perng

Taipei Veterans General Hospital

Also Known As

R P Perng, R Perng, R-P Perng, R. Perng, R.-P. Perng, R.P Perng, R.P. Perng, Reury P. Perng, Reury-Perng Perng

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Taipei Veterans General Hospital National Yang Ming Chiao Tung University The University of Texas MD Anderson Cancer Center National Health Research Institutes National Yang Ming University Hospital

About

R.-P. Perng is an author at Taipei Veterans General Hospital specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	17	757
2	Health Sciences	6	6	241
3	Cell Biology	6	6	350
4	Public Health	1	1	34
5	Biochemistry	1	1	11

R.-P. Perng

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Correlation of Intrinsic Chemoresistance of Non-Small-Cell Lung Cancer Cell Lines With HER-2/neu Gene Expression but Not With ras Gene Mutations Chun‐Ming Tsai, K.-T. Chang, R.-P. Perng, JNCI Journal of the National Cancer Institute	1993	175
Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines C.-M. Tsai, Karen Chang, Li‐Hwa Wu, Lung Cancer Tumor BiologyMedicineP53 Gene MutationsHer-2/neu Gene ExpressionCancer Genomics	1996	104
Enhanced Chemoresistance by Elevation of p185neu Levels in HER-2/neu-Transfected Human Lung Cancer Cells Chih–Chien Tsai, Dihua Yu, K.-T. Chang, JNCI Journal of the National Cancer Institute Tumor BiologyVeterans General Hospital-taipeiP185neu LevelsP185 Neu LevelsMedicine	1995	90
Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Chun‐Ming Tsai, A Levitzki, Li‐Hwa Wu, PubMed Tumor BiologyMedicinePharmacologyTyrphostin Ag825Cell Lines	1996	87
Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis Kuang‐Yao Yang, Yan-Ming Chen, Mingwei Huang, Japanese Journal of Clinical Oncology Surgical OncologyClinical SymptomsPathologyOncologySurgical Pathology	1997	71
Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated Y.-M. Chen, R.-P. Perng, Y.-C. Lee, Annals of Oncology Combination ChemotherapyMedicineSimilar EfficacyPharmacologyClinical Trials	2002	58
Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Ching‐Lung Lai, Chung-Hung Tsai, Tung-Ming Tsai, PubMed Anti-p53 AbsMedicineImmunologyPathologyPleural Effusion	1998	55
Tuberculous subcutaneous abscess: An analysis of seven cases C.H. Chen, Jen-Fu Shih, L.-S. Wang, Tubercle and Lung Disease Tuberculous Subcutaneous AbscessPulmonary TuberculosisClinical MicrobiologyTuberculosis	1996	55
Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR). J. Lee, Vera Hirsh, K. Park, Journal of Clinical Oncology Vandetanib Versus PlaceboAdvanced NsclcPrior TherapyVandetanib Vs PlaceboVandetanib 300	2010	52
Serum Cytokine Level Fluctuations in Chemotherapy-induced Myelosuppression Yan-Ming Chen, Jacqueline Whang‐Peng, J.-M. Liu, Japanese Journal of Clinical Oncology	1996	38

Page 1